Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
Inflammatory Bowel Disease
•
LFT abnormalities
•
JAK Inhibitors
•
Gastroenterology
•
General Hepatology
Would you prescribe a JAK inhibitor in patients with baseline transaminase elevation?
Related Questions
How would you manage a patient with highly active ankylosing spondylitis, iritis and Crohn’s, controlled with weekly adalimumab with co-morbid IgG4RD and intolerance of azathioprine due to elevated LFTs?
Do you feel comfortable using Jak inhibitors in patients with a strong family history of CAD, but no other risk factors?
How do you approach managing nausea and GI side effects when initiating methotrexate?
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?
How would you approach the treatment of an SLE patient with refractory mucocutaneous ulcerations and lichenoid skin eruption despite treatment with MMF, Aza, Benlysta, Saphnelo, Rituximab, and JAK inhibitors?
How would you approach the workup of a patient with a history of HCC post-TARE with a recent non-viable MRI but a new portal vein thrombosis?
What is your approach to choosing a particular advanced therapy based on patient or disease factors when initiating treatment for moderate-severe IBD?
How do you approach monitoring when using combination JAK inhibitors and methotrexate in RA?
How do you approach patients with RA and severe bronchiectasis with associated findings of UIP?
Would you consider chemo-RT for duodenal adenocarcinoma s/p resection with at least 1 cm positive margin in a patient with a history of Crohn's disease?
